A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Boehringer Ingelheim9,571 enrolled

Overview

Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals

Study Type

OBSERVATIONAL

Enrollment

9,571

Conditions

Diabetes Mellitus, Type 2

Interventions

EmpagliflozinDRUG

drug

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11) * At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance® (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min, ATC A10BD20) Exclusion Criteria: * Any diagnosis of T1DM

Locations (1)

Diabetes Agenda 2010 GmbH

Mahlow, Germany

Outcomes

Primary Outcomes

Percentage of Participants With Previous Occurence of Cardiovascular Comorbidities

Percentage of patients with previous occurence of cardiovascular (CV) comorbidities, including myocardial infarction, stroke, coronary artery disease, peripheral arterial disease, congestive heart failure.

Time frame: At baseline.

Percentage of Participants With Previous Occurence of Other Typical Diabetes Complications

Percentage of participants with previous occurence of other typical diabetes complications, including, Neuropathy, Nephropathy, Chronic Kidney Disease, Microalbuminuria, Macroalbuminuria, estimated glomerular filtration rate (eGFR), diabetic foot syndrome, retinopathy (background and proliferative).

Time frame: At baseline.

Percentage of Participants With Antidiabetic and Cardiovascular Co-medication

Percentage of participants with antidiabetic and cardiovascular co-medication, including lipid-lowering agents, other antihypertensives, antiplatelets and anticoagulants.

Time frame: At baseline.

Secondary Outcomes

Percentage of Participants by Age Category

Percentage of participants by age category; younger than 65 (\< 65), from 65 to 74 (65 ≤ 75) , from 75 to 80 (75 - 80) , older than 80 (\> 80).

Time frame: At baseline.

Percentage of Male Participants

The percentage of male participants is reported.

Time frame: At baseline.

Weight of Participants

Weight of participants.

Time frame: At baseline.

Height of Participants

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.